



**WHAT IS CLAIMED AS NOVEL AND UNOBVIOUS
IN LETTERS PATENT OF THE UNITED STATES IS:**

1. A pharmaceutical or veterinary composition, comprising a carrier or diluent, and an active agent selected from
a dehydroepiandrosterone, or pharmaceutically or veterinarily acceptable salts thereof, the dehydroepiandrosterone having the chemical formula




(I)

wherein the broken line represents a single or a double bond; R is hydrogen or a halogen; the H at position 5 is present in the alpha or beta configuration or the compound of chemical formula I comprises a racemic mixture of both configurations; and R¹ is hydrogen or SO₂OM, wherein M is selected from H, Na, sulfatide -SO₂O-CH₂CHCH₂OCOR³; or phosphatide




wherein R² and R³, which may be the same or different, are straight or branched (C₁-C₁₄) alkyl or glucuronide



; and/or

a ubiquinone or pharmaceutically or veterinarily acceptable salt thereof,
wherein the ubiquinone has the chemical formula



wherein n is 1 to 12, the agent being present in an amount effective for altering
5 levels of, or sensitivity to, adenosine or adenosine receptors, adenosine in a
subject's tissue (s), or treating bronchoconstriction, lung inflammation or
allergies or a disease associated with either of them.

2. The composition of claim 1, wherein in the CoQ_n of formula II,
wherein n is 1 to 10.

10 3. The composition of claim 1, wherein in the CoQ_n of formula II,
wherein n is 6 to 10.

4. The composition of claim 3, wherein in the CoQ_n of formula II,
wherein n is 10.

5. The composition of claim 4, comprising about 0.1 to about 40%
15 w/w active agent.

6. The composition of claim 5, comprising about 1 to about 20% w/w
active agent.

7. The composition of claim 1, wherein the compound of formula (I)
is dehydroepiandrosterone, wherein R and R¹ are each hydrogen and the broken
20 line represents a double bond.

8. The composition of claim 1, wherein the compound of formula (I)
is 16- α bromoepiandrosterone, wherein R is Br, R¹ is H, and the broken line
represents a double bond.

Sub
A'
Cont.

094426-0440
FOI240-9244860

9. The composition of claim 1, wherein the compound of formula (I) is 16-alpha-fluoro epiandrosterone, wherein R is F, R¹ is H and the broken line represents a double bond.

10. The composition of claim 1, wherein the compound of formula (I) is etiocholanolone, wherein R and R¹ are each hydrogen and the broken line represents a double bond.

11. The composition of claim 1, wherein the compound of formula (I) is dehydroepiandrosterone sulfate, wherein R is H, R¹ is SO₂OM and M is a sulfatide group as defined above, and the broken line represents a single bond.

12. The composition of claim 1, wherein in the compound of formula (I), R is halogen selected from Br, Cl or F, R¹ is H, and the broken line represents a double bond.

13. The composition of claim 1, wherein the compound of formula (I) is 16-alpha-fluoro epiandrosterone.

14. The composition of claim 1, wherein the compound of formula (I) is selected from dehydroepiandrosterone, 16-alpha-bromoepiandrosterone, 16-alpha-fluoro epiandrosterone, etiocholanolone, dehydroepiandrosterone sulfate or pharmaceutically or veterinarily acceptable salts thereof.

15. The composition of claim 1, wherein the carrier or diluent comprises a pharmaceutically or veterinarily acceptable carrier or diluent.

16. The method of claim 15, wherein the carrier or diluent is selected from solid or liquid carriers or diluents, and the active agent comprises liquid or solid particles.

17. The composition of claim 15, further comprising an agent selected from folic acid, pharmaceutically or veterinarily acceptable salts of folic acid, other therapeutic agents, preservatives, antioxidants, flavoring agents, volatile oils, buffering agents, dispersants or surfactants.

18. The composition of claim 15, which is a systemic or topical formulation.

19. The formulation of claim 18, in the form of a formulation selected from buccal, sublingual, dermal, intraocular, vaginal, rectal, intraarticular, intrapulmonary respirable, oral, inhalable, nasal, topical, parenteral, or transdermal.

20. The formulation of claim 19, which is an oral formulation selected from the group consisting of capsules, cachets, lozenges, tablets, powder, granules, solutions, suspensions and emulsions.

21. The oral formulation of claim 19, which is a solution, suspension or emulsion selected from the group consisting of aqueous and non-aqueous liquid solutions and suspensions and oil-in-water and water-in-oil emulsions.

22. The oral formulation of claim 19, which is a buccal or sub-lingual formulation selected from the group consisting of lozenges further comprising a flavoring agent selected from the group consisting of sucrose, acacia and tragacanth; and pastilles further comprising an inert base selected from the group consisting of gelatin, glycerin, sucrose and acacia.

23. The oral formulation of claim 20, further comprising an enteric coating.

24. The formulation of claim 1, which is a parenteral formulation.

25. The parenteral formulation of claim 24, in injectable form.

26. The parenteral formulation of claim 24, selected from subcutaneous, intradermal, intramuscular, or intravenous formulations.

27. The injectable formulation of claim 24, selected from injectable solutions or suspensions, and which may further comprise folic acid, pharmaceutically or veterinarily acceptable salts thereof, other therapeutic agents, antioxidants, buffers, bacteriostatic agents or solutes which render the solution or suspension isotonic with the blood of any intended recipient.

28. The injectable formulation of claim 27, wherein the solutions or suspensions are selected from sterile aqueous or non-aqueous injection solutions or suspensions, which may further comprise suspending agents or thickening agents.

5 29. The composition of claim 1 in bulk or in single or multi-dose form.

30. The composition of claim 29, wherein the single or multi-dose form is provided in sealed ampoules or vials.

31. The composition of claim 1, which is freeze-dried or lyophilized.

32. The formulation of claim 19, which is a topical formulation
10 selected from ointments, creams, lotions, pastes, gels, sprays, aerosols or oils, which may further comprise a carrier selected from vaseline, lanoline, polyethylene glycols, alcohols or trans-dermal enhancers.

33. The formulation of claim 19, which is a transdermal formulation in the form of a patch.

15 34. The transdermal formulation of claim 33, which is an iontophoretic formulation selected from iontophoretic solutions or suspensions, and which may further comprise a buffer.

35. The formulation of claim 19, which is an inhalable, respirable, intrapulmonary or nasal formulation.

20 36. The inhalable or respirable formulation of claim 35, which is an aerosol or spray comprising liquid or solid particles of the active agent, and which may further comprise an ingredient selected from folic acid, other therapeutic agents, preservatives, antioxidants, flavoring agents, volatile oils, buffering agents, dispersants or surfactants.

25 37. The formulation of claim 36, comprising an inhalable or respirable formulation comprising powdered or liquid particles of the active agent about 0.05 to about 10 μ in size.

38. The formulation of claim 37, comprising an inhalable or respirable

09841426-042401
A2

*Sub
A2
cont.*

aerosol formulation comprising powdered or liquid particles of the active agent about 0.1 to 5 μ in size.

39. The formulation of claim 36, which comprises a nasal or intrapulmonary aerosol formulation comprising powdered or liquid particles of the active agent about 10 to about 100 μ in size.

*Sub
A3*

40. The formulation of claim 39, which comprises powdered or liquid particles of the active agent about 10 to 50 μ in size.

41. The formulation of claim 16, wherein the carrier comprises a hydrophobic carrier.

10 42. A kit comprising the formulation of claim 15, and a delivery device.

43. The kit of claim 42, wherein the formulation comprises an inhalable, respirable, intrapulmonary or nasal formulation, and the delivery device comprises an inhaler provided with an aerosol generating means.

15 44. The kit of claim 42, wherein the delivery device delivers individual pre-metered doses of the formulation.

45. The kit of claim 42, wherein the delivery device comprises an inhaler.

46. The kit of claim 42, wherein the inhaler comprises a nebulizer or insufflator.

20 47. The kit of claim 42, wherein the delivery device comprises a compression inhaler, and the formulation comprises a suspension or solution in an aqueous or non-aqueous liquid or an oil-in-water or water-in-oil emulsion.

48. The kit of claim 41, wherein the formulation is provided in a pierceable or openable capsule or cartridge.

25 49. An in vivo method of preventing or treating a disorder or condition associated with abnormal levels of adenosine or adenosine receptors, or sensitivity to adenosine in a subject's tissue(s), bronchoconstriction, lung inflammation or

allergies, wheezing, difficult breathing, impeded airways, asthma, COPD, CF, ARDS, RDS, decreased lung surfactant, pulmonary fibrosis, allergic rhinitis, or cancer, comprising administering to a subject in need of treatment a therapeutic amount of the active composition of claim 1, wherein when the epiandrosterone is
5 the sole agent and the disease or condition is steroid induced asthma, the composition may not comprise a steroid.

50. The method of claim 49, wherein the disorder or condition is associated with bronchoconstriction, impeded respiration or wheezing.

51. The method of claim 49, wherein the active agent comprises a
10 dehydroepiandrosterone of chemical formula (I) or its salt.

52. The method of claim 51, wherein the epiandrosterone salt comprises dehydroepiandrosterone sulfate.

53. The method of claim 51, wherein the active agent comprise dehydroepiandrosterone (DHEA).

54. The method of claim 49, wherein epiandrosterone or salt thereof, is
15 administered in an amount of about 0.05 to about 1,000 mg/kg body weight.

55. The method of claim 51, wherein the epiandrosterone or salt thereof is administered in an amount of about 1 to about 600 mg/kg body weight.

56. The method of claim 51, wherein the epiandrosterone or salt
20 thereof is administered in an amount of about 5 to about 200 mg/kg body weight.

57. The method of claim 49, wherein the active agent is a ubiquinone of chemical formula (II) or salt thereof.

58. The method of claim 57, wherein the ubiquinone or salt thereof is administered in an amount of about 1 to about 1200 mg/kg body weight.

59. The method of claim 58 herein the ubiquinone or salt thereof is
25 administered in an amount of about 30 to about 600 mg/kg body weight.

60. The method of claim 59, wherein the ubiquinone or salt thereof is administered in an amount of about 50 to about 150 mg/kg.

61. The method of claim 49, further comprising administering folinic acid or a salt thereof.

62. The method of claim 61, wherein the folinic acid is administered in an amount about 1 to about 1,000 mg/kg body weight.

5 63. The method of claim 62, wherein the folinic acid is administered in an amount of about 5 to about 500 mg/kg body weight.

64. The method of claim 49, wherein the disorder or condition is chronic obstructive pulmonary disease (COPD).

65. The method of claim 49, wherein the disorder or condition is acute
10 respiratory distress syndrome (ARDS).

66. The method of claim 49, wherein the disorder or condition comprises lung inflammation or allergy(ies).

67. The method of claim 49, wherein the disorder or condition comprises pulmonary fibrosis.

15 68. The method of claim 49, wherein the disorder or condition comprises allergic rhinitis.

69. The method of claim 49, wherein the disorder or condition comprises infantile respiratory distress syndrome (RDS).

70. The method of claim 49, wherein the disorder or condition
20 comprises cystic fibrosis (CF).

71. The method of claim 49, wherein the disorder or condition comprises impeded respiration or lung pain.

72. The method of claim 49, wherein the disorder or condition comprises decreased lung surfactant.

25 73. The method of claim 49, wherein the disorder or condition comprises lung cancer.

74. The method of claim 49, wherein the active agent comprises a ubiquinone and an epiandrosterone or their salts, and they are administered concurrently.

5 75. The method of claim 74, wherein the epiandrosterone and the ubiquinone or their salts are administered in the same formulation.

76. The method of claim 74, wherein the epiandrosterone and the ubiquinone or their salts are administered in different formulations.

77. The method of claim 49, wherein the subject is a human or non-human animal.

10 78. The method of claim 49, which is a prophylactic or therapeutic method.

79. The method of claim 49, wherein the subject is in need of treatment to reduce or deplete adenosine levels and/or increase ubiquinone levels.

0941426.043401
FOIA b 7 - D